October 11, 2006
The clinical trial “GVAX Cancer Vaccine” started in January 2006 and enrollment is still open to new patients. So far 11 patients were selected to participate in the trial. Eight of those patients have the diagnosis of Alveolar Soft Part Sarcoma (ASPS). All the eight ASPS patients have completed the study. There have been no serious toxicities associated with the GVAX cancer vaccine and it has been tolerated extremely well.
Encouraging evidence of biological activity was observed in skin biopsies from sites that were injected with killed tumor samples, after patients had received the vaccine. In one case, biological activity was noted in a tumor that was resected from a patient at the end of the vaccination period.
Patients who participated in the Cancer Vaccine GVAX trial have now the option to join, within 4 months following the end of their last injection, to an additional clinical trial that uses injections of gamma interferon and GMCSF. Co-injections of gamma interferon and GMCSF aim to maintain and /or increase the body’s immune response to alveolar soft part sarcoma cancer cells.
It is too early in the study to make any clinical interpretations and some laboratory studies are still on – going as well.
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)